Northview Ventures

The Medical Aesthetics Group is a consultancy firm that specializes in the medical aesthetics industry. It offers tailored business plans and recruitment services designed to enhance operational effectiveness and profitability for its clients. By providing expertise and resources specific to the sector, the company aims to help businesses increase revenue and drive growth. Its customizable approach ensures that clients receive the support they need to succeed in a competitive market.

Amp Human is a venture-backed startup based in Park City, Utah, focused on developing innovative products to enhance human performance. The company utilizes a unique platform technology rooted in biotechnology, which allows for the transdermal delivery of nutrients. This approach addresses a significant barrier to human optimization, specifically the limitations posed by the gut. Amp Human's flagship product is an electrolyte lotion designed to neutralize acid buildup during exercise. Utilizing patent-pending skin absorption technology, the lotion enhances the body's bicarbonate levels, helping athletes to extend their performance capabilities regardless of their physical constraints.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Deep Surface AI specializes in developing advanced 3D visualization software for facial aesthetics, utilizing machine learning and extensive datasets that include 3D facial models and aesthetic information. The company's platform aims to streamline the cosmetic surgery process by providing surgeons with precise and efficient tools to produce personalized morphs for patients. This technology not only enhances the surgical planning experience but also offers patients and those interested in aesthetics realistic visualizations of potential outcomes. By automating and improving the morphing process, Deep Surface AI facilitates better communication between surgeons and patients, ultimately enhancing the overall experience in cosmetic procedures.

MindMics is an innovative wearable technology company focused on health monitoring through sound-based platforms integrated into earbuds and hearing aids. By capturing clinically meaningful biometrics in real-time, such as circadian rhythms, breathing rates, body temperature, and heartbeats, MindMics aims to enhance mental performance and overall well-being. The technology allows users to gain insights into their health, facilitating improved focus, satisfaction, and mindfulness. Through this approach, MindMics seeks to provide users with tailored products and experiences that promote mental peace and enhance daily living.

Provider of health consultation services intended to help clients improve their energy, wellbeing and achieve the results. The company offers transformative health plans, immersive retreats and one-to-one and group coaching programmes, helping individuals to be happier, healthier and achieve more through the creation of optimal health.

Total Flow Medical is a medical device startup focused on enhancing the quality of life for patients undergoing cardiac surgery and life support. The company is developing innovative medical devices aimed at preventing injuries in patients who require extracorporeal circulation. Its initial product is a user-friendly cannula designed for minimally invasive cardiopulmonary bypass surgery, which helps reduce the risks of injury and death associated with traditional invasive procedures.

Elevate Farms Inc. is a technology-driven indoor farming company based in Toronto, Canada, specializing in vertically stacked cultivation of leafy green vegetables. Established in 2017, the company employs proprietary technology to optimize plant growth and maximize space utilization, utilizing state-of-the-art LED lighting, automated nutrient delivery systems, and climate-controlled environments. This innovative approach not only enhances crop yields and nutritional quality but also significantly reduces water usage and land requirements compared to traditional farming methods. Committed to sustainability, Elevate Farms aims to minimize its environmental impact by conserving resources and integrating energy-efficient designs. The company operates facilities in three countries and is focused on expanding its global presence, addressing the rising demand for sustainable produce. By prioritizing high-volume, efficient production, Elevate Farms successfully demonstrates that vertical farming can be profitable while enhancing supply chain efficiencies. As it continues to advance its technology and practices, Elevate Farms positions itself as a leader in transforming agriculture to meet 21st-century food security challenges.

CareSpan Health operates a virtual healthcare clinic that facilitates the delivery of comprehensive medical care to patients through the Internet. The company offers a digital care platform that combines various digital tools, capabilities, and data to support healthcare providers. This integrated platform addresses the growing shortage of primary and urgent care services, as well as behavioral and mental health support. By enabling providers to deliver care remotely, CareSpan Health enhances access to medical services for patients and streamlines the healthcare delivery process.

Renaissance BioScience Corp. is a biotechnology company based in Vancouver, Canada, that specializes in developing proprietary yeast-based platform technologies aimed at addressing various industrial and health challenges. Founded in 2013, the company focuses on creating functional microorganisms for the food, beverage, agriculture, and pharmaceutical industries. Its innovative yeast strains are designed to reduce acrylamide levels in carbohydrate-rich foods and to prevent hydrogen sulfide formation in alcoholic beverages such as wine, beer, and cider. Additionally, Renaissance BioScience is involved in pioneering research, including the development of RNA delivery systems for therapeutic applications and biopesticides for crop protection. The company's commitment to sustainability and health drives its mission to provide market-ready solutions that enhance safety and efficacy across multiple sectors.

CureVac is a clinical-stage biopharmaceutical company based in Germany, established in 2000, that specializes in developing vaccines and therapies utilizing messenger ribonucleic acid (mRNA). The company focuses on both prophylactic and therapeutic applications of mRNA, enabling the human body to produce proteins that combat various diseases. CureVac's innovative pipeline includes mRNA-based cancer immunotherapies, such as CV9104, which is in Phase IIb development for prostate cancer, as well as RNActive vaccines against infectious diseases and RNArt molecular therapies designed to stimulate the production of therapeutic proteins. Additionally, the company has collaborated with GSK to advance second-generation vaccines for seasonal influenza and COVID-19, alongside an avian influenza vaccine, while also exploring mRNA therapies for oncology and other conditions affecting the liver and eyes.

Precision Nanosystems specializes in the development of tools and processes for the creation and manufacturing of nanoparticles used in medicine and medical research. The company offers a range of products, including the NanoAssemblr benchtop instrument, which facilitates the prototyping of nanoparticles and the development of nanoparticle-based drugs that deliver RNA, small molecules, and protein therapeutics. Additionally, Precision Nanosystems provides various kits, such as Neuro9Kit for studying gene function in neurons and glial cells, Test9Kit for gene function studies in diverse cell types, and Hepato9Kit for liver gene function analysis. Their microfluidic devices enable the rapid and cost-effective manufacturing of lipid nanoparticles that can encapsulate and deliver bioactive agents, supporting life sciences researchers in developing innovative treatments and therapies for various diseases.

Perimeter Medical Imaging AI is a medical technology company focused on revolutionizing cancer surgery through the development of ultra-high-resolution, real-time imaging tools. These advanced imaging solutions are designed to address significant unmet medical needs in the surgical field, enhancing the ability to detect and delineate cancerous tissues during procedures. By improving the accuracy of surgical interventions, Perimeter aims to optimize patient outcomes and contribute to more effective cancer treatment strategies.

Synaptive Medical Inc. is a Toronto-based medical device company that specializes in neurosurgery and medical imaging. Founded in 2012, the company develops integrated systems that encompass informatics, imaging, surgical planning, navigation, and advanced optics to enhance patient care in and beyond the operating room. Its product offerings include BrightMatter Prime for pre-operative planning, BrightMatter Servo for high-definition imaging and navigation, and ImageDrive, a web-enabled solution for managing patient data. Additionally, Synaptive Medical provides tools like BrightMatter Simulate for training, BrightMatter Plan for automated tractography, and BrightMatter Guide for 3D visualization in the surgical suite. The company aims to improve surgical outcomes through collaboration with healthcare professionals, providing innovative solutions that facilitate better patient management and recovery.

AbCellera is a biotechnology company specializing in antibody discovery and development. It uses an integrated platform combining proprietary hardware, software, tools, and advanced data science to efficiently identify and develop optimal antibodies for clinical use. The company partners with both emerging biotechs and established pharmaceutical companies, leveraging its expertise to accelerate the drug development process and improve patient outcomes.

Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company based in Vancouver, Canada, focused on the development and commercialization of innovative drug delivery methods in various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets several products, such as Vistita, which reduces intraocular pressure in patients with glaucoma, and Tacrolimus IR, an immunosuppressant used in organ transplantation. Additionally, Aequus offers Evolve dry eye products that address symptoms like discomfort and dryness, as well as preservative-free ophthalmic solutions. The company's development pipeline includes extended-release oral tablets for epilepsy and cannabinoid-based therapeutics for neurological disorders. Aequus has established collaboration agreements with several partners to enhance its product offerings and market reach. Founded in 2013, Aequus Pharmaceuticals aims to improve patient compliance and therapeutic outcomes through its innovative approaches.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates aimed at treating epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, Xenon is developing XEN007, a central nervous system-acting calcium channel modulator, also in Phase I trials. The company leverages insights from genetic research, particularly from families with severe phenotypes, to identify drug targets, which may extend beyond rare genetic disorders. Furthermore, Xenon has established a collaboration with Neurocrine Biosciences to advance the development of innovative epilepsy treatments.